Amedisys (AMED) Tops Q2 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts AMED Hot Sheet
Price: $100.99 --0%
Financial Fact:
Total other expense, net: 3.84M
Today's EPS Names:
FUSE, INM, TRI, More
Financial Fact:
Total other expense, net: 3.84M
Today's EPS Names:
FUSE, INM, TRI, More
Join SI Premium – FREE
Amedisys (NASDAQ: AMED) reported Q2 EPS of $1.00, $0.22 better than the analyst estimate of $0.78. Revenue for the quarter came in at $411.6 million versus the consensus estimate of $403.62 million.
GUIDANCE:
Amedisys sees FY2018 EPS of $3.32-$3.41, versus the consensus of $3.10. Amedisys sees FY2018 revenue of $1.63-1.65 million, versus the consensus of $1.63 million.
For earnings history and earnings-related data on Amedisys (AMED) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Comscore (SCOR) Misses Q3 EPS by 446c
- JELD-WEN Holding, Inc. (JELD) Tops Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
